Toll Free: 1-888-928-9744

Oxford BioMedica plc - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Oxford BioMedica plc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Oxford BioMedica plc - Product Pipeline Review - 2014', provides an overview of the Oxford BioMedica plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Oxford BioMedica plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Oxford BioMedica plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Oxford BioMedica plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Oxford BioMedica plc's pipeline products

Reasons to buy

- Evaluate Oxford BioMedica plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Oxford BioMedica plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Oxford BioMedica plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Oxford BioMedica plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oxford BioMedica plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Oxford BioMedica plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Oxford BioMedica plc Snapshot 5
Oxford BioMedica plc Overview 5
Key Information 5
Key Facts 5
Oxford BioMedica plc - Research and Development Overview 6
Key Therapeutic Areas 6
Oxford BioMedica plc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Oxford BioMedica plc - Pipeline Products Glance 15
Oxford BioMedica plc - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Oxford BioMedica plc - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Oxford BioMedica plc - Drug Profiles 18
TroVax 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ProSavin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RetinoStat 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
EncorStat 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
EndoAngio-GT 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Glaucoma-GT 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MoNuDin 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
OXB-102 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Oxford BioMedica plc - Pipeline Analysis 29
Oxford BioMedica plc - Pipeline Products by Target 29
Oxford BioMedica plc - Pipeline Products by Route of Administration 30
Oxford BioMedica plc - Pipeline Products by Molecule Type 31
Oxford BioMedica plc - Pipeline Products by Mechanism of Action 32
Oxford BioMedica plc - Recent Pipeline Updates 33
Oxford BioMedica plc - Dormant Projects 39
Oxford BioMedica plc - Company Statement 40
Oxford BioMedica plc - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44
List of Tables
Oxford BioMedica plc, Key Information 5
Oxford BioMedica plc, Key Facts 5
Oxford BioMedica plc - Pipeline by Indication, 2014 8
Oxford BioMedica plc - Pipeline by Stage of Development, 2014 9
Oxford BioMedica plc - Monotherapy Products in Pipeline, 2014 10
Oxford BioMedica plc - Partnered Products in Pipeline, 2014 11
Oxford BioMedica plc - Partnered Products/ Combination Treatment Modalities, 2014 12
Oxford BioMedica plc - Out-Licensed Products in Pipeline, 2014 13
Oxford BioMedica plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Oxford BioMedica plc - Phase II, 2014 15
Oxford BioMedica plc - Phase I, 2014 16
Oxford BioMedica plc - Preclinical, 2014 17
Oxford BioMedica plc - Pipeline by Target, 2014 29
Oxford BioMedica plc - Pipeline by Route of Administration, 2014 30
Oxford BioMedica plc - Pipeline by Molecule Type, 2014 31
Oxford BioMedica plc - Pipeline Products by Mechanism of Action, 2014 32
Oxford BioMedica plc - Recent Pipeline Updates, 2014 33
Oxford BioMedica plc - Dormant Developmental Projects,2014 39
Oxford BioMedica plc, Subsidiaries 42 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify